Title: Pharmacokinetics of daikenchuto, a traditional Japanese medicine (Kampo) after. single oral administration to healthy Japanese volunteers

Transcription

1 Title: Pharmacokinetics of daikenchuto, a traditional Japanese medicine (Kampo) after single oral administration to healthy Japanese volunteers Authors: Masaya Munekage, Hiroyuki Kitagawa, Kengo Ichikawa, Junko Watanabe, Katsuyuki Aoki, Toru Kono, Kazuhiro Hanazaki Journal: Drug Metabolism Disposition

2 Supplemental Figure 1. Structural formulas of TJ-100 ingredients and ISs

3 Supplemental Table 1. Summary of assay method (Zanthoxylum Fuit) Analyte Internal standard LC-MS/MS system Biological sample and volume Calibration curve range Hydroxy-α-sanshool(), Hydroxy-β-sanshool() Schizandrin API5000 (AB SCIEX) Human plasma 0.5 ml 0.01 to 10 ng/ml LC-MS/MS conditions Analytical column YMC-Pack ODA-AQ, 3 μm, mm I.D. (YMC Co., Ltd.) Guard column YMC-Pack ODA-AQ, 3 μm, mm I.D. (YMC Co., Ltd.) Mobile phase 0.2 vol% Acetic acid in water/acetonitrile (55:45, v/v) Flow rate 0.2 ml/min Column temp 40 C Autosampler temp 7 C Injection volume 20 µl Analytical time 15 min Ionization mode ESI (Electrospray ionization, Turbo ion spray probe), positive Scan mode MRM (multiple reaction monitoring) Monitoring ion hydroxy-α-sanshool m/z m/z hydroxy-β-sanshool m/z m/z Schizandrin m/z m/z Optimized mass spectrometer acquisition parameters used for analyte quantitation CUR (psi) 40 GS1 (psi) 50 GS2 (psi) 60 TEM ( ) 600 CAD (psi) 8 CE (V) 23 CUR, Curtain Gas; GS, Ion source gas; TEM, Temperature; CAD, Collision Gas; CE, Collision energy.

4 Validation results Selectivity Recovery 0.05, 8 ng/ml Linearity 0.01, 0.02, 0.05, 0.1, 0.5, 1, 5, 10 ng/ml Limits of quantification 0.01, 10 ng/ml Hydroxy-α-sanshool No interfering Hydroxy-β-sanshool No interfering Schizandrin (IS) No interfering 0.05 ng/ml ± 7.4 % 8 ng/ml 81.3 ± 6.7 % 0.05 ng/ml 93.2 ± 8.4 % 8 ng/ml 85.2 ± 3.5 % Schizandrin (IS) 8 ng/ml 91.0 ± 2.1 % Correlation coefficient (r) to LLOQ RE: -2.6 to 8.0 % Others RE: to 15.0 % Correlation coefficient (r) to LLOQ RE: -2.7 to 7.0 % Others RE: to 14.0 % LLOQ RE: -1.1 % ULOQ RE: 9.0 % LLOQ CV: 12.0 % Precision ULOQ CV: 3.7 % LLOQ RE: -5.2 % ULOQ RE: 2.0 % LLOQ CV: 11.6 % Precision ULOQ CV: 2.0 %

5 Intra-batch 0.02, 0.5, 8 ng/ml Inter-batch 0.02, 0.5, 8 ng/ml Stability in Plasma (Short-term Stability) 0.02, 8 ng/ml Room temperature, for 1h, 4h 0.02 ng/ml RE: 2.5 % 0.5 ng/ml RE: % 8 ng/ml RE: 2.8 % 0.02 ng/ml CV: 8.3 % Precision 0.5 ng/ml CV: 2.5 % 8 ng/ml CV: 1.3 % 0.02 ng/ml RE: -0.5 % 0.5 ng/ml RE: -6.8 % 8 ng/ml RE: -0.5 % 0.02 ng/ml CV: 7.0 % Precision 0.5 ng/ml CV: 1.9 % 8 ng/ml CV: 2.3 % 0.02 ng/ml RE: -1.5 % 0.5 ng/ml RE: -1.2 % 8 ng/ml RE: 6.9 % 0.02 ng/ml CV: 8.1 % Precision 0.5 ng/ml CV: 9.5 % 8 ng/ml CV: 4.2 % 0.02 ng/ml RE: -3.0 % 0.5 ng/ml RE: 1.4 % 8 ng/ml RE: 6.9 % 0.02 ng/ml CV: 5.7 % Precision 0.5 ng/ml CV: 6.3 % 8 ng/ml CV: 5.6 % 1h 0.02 ng/ml RR: % 8 ng/ml RR: % 4h 0.02 ng/ml RR: % 8 ng/ml RR: 98.7 % 1h 0.02 ng/ml RR: 94.5 % 8 ng/ml RR: % 4h 0.02 ng/ml RR: % 8 ng/ml RR: 99.0 %

6 Stability in Plasma (long-term Stability) 0.02, 8 ng/ml at -20, for 1 week, 2 weeks, 1 month, 2 months, and 6 months Post-preparative stability (Stability in Extract) 0.02, 8 ng/ml in auto-sampler set at 7, for 24h Freeze and Thaw Stability 1 week 0.02 ng/ml RR: % 8 ng/ml RR: % 2 weeks 0.02 ng/ml RR: % 8 ng/ml RR: % 1 month 0.02 ng/ml RR: 95.1 % 8 ng/ml RR: 91.1 % 2 months 0.02 ng/ml RR: % 8 ng/ml RR: 98.5 % 6 months 0.02 ng/ml RR: % 8 ng/ml RR: 90.9 % 1 week 0.02 ng/ml RR: % 8 ng/ml RR: % 2 weeks 0.02 ng/ml RR: % 8 ng/ml RR: % 1 month 0.02 ng/ml RR: % 8 ng/ml RR: % 2 months 0.02 ng/ml RR: % 8 ng/ml RR: % 6 months 0.02 ng/ml RR: 96.5 % 8 ng/ml RR: 90.6 % 0.02 ng/ml RR: 90.6 % 24h 8 ng/ml RR: 92.9 % 0.02 ng/ml RR: 95.0 % 24h 8 ng/ml RR: 98.5 % 3 cycle 0.02 ng/ml RR:98.5 % 8 ng/ml RR: 86.8 % 3 cycle 0.02 ng/ml RR:107.0 % 8 ng/ml RR: %

7 Appropriateness of Dilution Method (using blank plasma) 50 ng/ml 10-fold RE: 4.6 % Precision CV: 3.6 % 100-fold RE: 9.0 % Precision CV: 3.9 % 10-fold RE: 10.8 % Precision CV: 3.2 % 100-fold RE: 5.4 % Precision CV: 1.7 %

8 Supplemental Table 2. Summary of assay method (Processed ginger) Analyte Internal standard LC/MS/MS system Biological sample and volume Calibration curve range [6]-shogaol(), [10]-shogaol() Nonivamide API5000 (AB SCIEX) Human plasma 0.5 ml 0.02 to 10 ng/ml LC-MS/MS conditions Analytical column YMC-Pack ODA-AQ, 3 μm, mm I.D. (YMC Co., Ltd.) Guard column YMC-Pack ODA-AQ, 3 μm, mm I.D. Mobile phase (A) 0.2 vol% Acetic acid in water (B) 0.2 vol% Acetic acid in acetonitrile gradient of % (B) over 15 min Flow rate 0.2 ml/min (0 to 12 min), 0.3 ml/min (12.1 to 15.0 min) Column temp 40 C Autosampler temp 7 C Injection volume 20 µl Analytical time 15 min Ionization mode ESI (Electrospray ionization, Turbo ion spray probe), positive Scan mode MRM (multiple reaction monitoring) Monitoring ion [6]-shogaol m/z m/z [10]-shogaol m/z m/z Nonivamide m/z m/z Optimized mass spectrometer acquisition parameters used for analyte quantitation CUR (psi) 40 GS1 (psi) 60 GS2 (psi) 40 TEM ( ) 700 CAD (psi) 4 CE (V) 17([6]-shogaol), 25([10]-shogaol) CUR, Curtain Gas; GS, Ion source gas; TEM, Temperature; CAD, Collision Gas; CE, Collision energy.

9 Validation results Selectivity Recovery 0.05, 8 ng/ml Linearity 0.02, 0.05, 0.1, 0.5, 1, 5, 10 ng/ml Limits of quantification 0.01, 10 ng/ml No interfering No interfering Nonivamide (IS) No interfering 0.05 ng/ml 79.7 ± 1.2 % 8 ng/ml 79.3 ± 0.8 % 0.05 ng/ml 15.5 ± 0.1 % 8 ng/ml 15.3 ± 0.3 % Nonivamide (IS) 8 ng/ml 93.6 ± 0.9 % Correlation coefficient (r) to LLOQ RE: -2.0 to 6.0 % Others RE: to 9.0 % Correlation coefficient (r) to LLOQ RE: -5.5 to 5.0 % Others RE: to 14.8 % LLOQ RE: -2.5 % ULOQ RE: 1.0 % Precision LLOQ CV: 1.5 % ULOQ CV: 1.0 % LLOQ RE: 9.0 % ULOQ RE: % Precision LLOQ CV: 4.1 % ULOQ CV: 1.5 %

10 Intra-batch 0.05, 0.5, 8 ng/ml Inter-batch 0.05, 0.5, 8 ng/ml Stability in Plasma (Short-term Stability) 0.05, 8 ng/ml Room temperature, for 1h, 4h 0.05 ng/ml RE: 1.4 % 0.5 ng/ml RE: 5.2 % 8 ng/ml RE: 0.8 % 0.05 ng/ml CV: 1.4 % Precision 0.5 ng/ml CV: 3.0 % 8 ng/ml CV: 2.9 % 0.05 ng/ml RE: 6.6 % 0.5 ng/ml RE: -5.8 % 8 ng/ml RE: 4.4 % 0.05 ng/ml CV: 3.8 % Precision 0.5 ng/ml CV: 10.8 % 8 ng/ml CV: 6.5 % 0.05 ng/ml RE: -1.4 % 0.5 ng/ml RE: 2.4 % 8 ng/ml RE: 0.5 % 0.05 ng/ml CV: 3.2 % Precision 0.5 ng/ml CV: 3.1 % 8 ng/ml CV: 4.7 % 0.05 ng/ml RE: 0.4 % 0.5 ng/ml RE: -1.8 % 8 ng/ml RE: 5.5 % 0.05 ng/ml CV: 11.8 % Precision 0.5 ng/ml CV: 10.6 % 8 ng/ml CV: 8.1 % 1h 0.05 ng/ml RR: 99.6 % 8 ng/ml RR: 98.7 % 4h 0.05 ng/ml RR: 94.6 % 8 ng/ml RR: 95.3 % 1h 0.05 ng/ml RR: % 8 ng/ml RR: 99.8 % 4h 0.05 ng/ml RR: % 8 ng/ml RR: %

11 Stability in Plasma (long-term Stability) 0.05, 8 ng/ml at -20, for 1 week, 2 weeks, 1 month, 2 months, and 6 months Post-preparative stability (Stability in Extract) 0.05, 8 ng/ml in auto-sampler set at 7, for 24h Freeze and Thaw Stability 1 week 0.05 ng/ml RR: 96.7 % 8 ng/ml RR: % 2 week 0.05 ng/ml RR: 99.8 % 8 ng/ml RR: % 1 month 0.05 ng/ml RR: 97.5 % 8 ng/ml RR: % 2 month 0.05ng/mL RR: 96.9 % 8 ng/ml RR: % 6 month 0.05 ng/ml RR: 99.0 % 8 ng/ml RR: % 1 week 0.05 ng/ml RR: 98.5 % 8 ng/ml RR: 91.1 % 2 week 0.05 ng/ml RR: 85.4 % 8 ng/ml RR: 95.7 % 1 month 0.05 ng/ml RR: 93.3 % 8 ng/ml RR: % 2 month 0.05ng/mL RR: 97.2 % 8 ng/ml RR: 96.8 % 6 month 0.05 ng/ml RR: 85.6 % 8 ng/ml RR: 88.4 % 0.05 ng/ml RR: % 24h 8 ng/ml RR: % 0.05 ng/ml RR: % 24h 8 ng/ml RR: % 3 cycle 0.05 ng/ml RR:86.9 % 8 ng/ml RR: % 3 cycle 0.05 ng/ml RR:88.0 % 8 ng/ml RR: %

12 Appropriateness of Dilution Method (using blank plasma) 50 ng/ml 10-fold RE: 8.4 % Precision CV: 1.7 % 100-fold RE: 1.4 % Precision CV: 1.0 % 10-fold RE: 1.6 % Precision CV: 1.8 % 100-fold RE: 2.0 % Precision CV: 1.2 %

13 Supplemental Table 3. Summary of assay method (Ginseng) Analyte Internal standard LC/MS/MS system Biological sample and volume Calibration curve range Ginsenoside Rb 1 (), Ginsenoside Rg 1 () Asiaticoside API5000 (AB SCIEX) Human plasma 0.5 ml 0.01 to 10 ng/ml LC-MS/MS conditions Analytical column YMC-Pack ODA-AQ, 3 μm, mm I.D. Guard column YMC-Pack ODA-AQ, 3 μm, mm I.D. Mobile phase (A) 0.2 vol% Acetic acid in water (B) 0.2 vol% Acetic acid in acetonitrile gradient of % (B) over 15 min Flow rate 0.2 ml/min (0 to 12 min), 0.3 ml/min (12.1 to 15.0 min) Column temp 40 C Autosampler temp 7 C Injection volume 20 µl Analytical time 15 min Ionization mode ESI (Electrospray ionization, Turbo ion spray probe), positive Scan mode MRM (multiple reaction monitoring) Monitoring ion ginsenoside Rb 1 m/z m/z ginsenoside Rg 1 m/z m/z Asiaticoside m/z m/z Optimized mass spectrometer acquisition parameters used for analyte quantitation CUR (psi) 20 GS1 (psi) 80 GS2 (psi) 10 TEM ( ) 450 CAD (psi) 4 CE (V) 30 (ginsenoside Rb 1 ), 13 (ginsenoside Rg 1 ) CUR, Curtain Gas; GS, Ion source gas; TEM, Temperature; CAD, Collision Gas; CE, Collision energy.

14 Validation results Selectivity Recovery 0.05, 8 ng/ml Linearity 0.01, 0.02, 0.05, 0.1, 0.5, 1, 5, 10 ng/ml Limits of quantification 0.01, 10 ng/ml No interfering No interfering Asiaticoside (IS) No interfering 0.05 ng/ml 57.1 ± 4.0 % 8 ng/ml 57.7 ± 1.9 % 0.05 ng/ml 81.1 ± 1.8 % 8 ng/ml 84.5 ± 5.2% Asiaticoside (IS) 8 ng/ml 72.4 ± 0.8 % Correlation coefficient (r) to LLOQ RE: -4.8 to 7.0 % Others RE: to 13.0 % Correlation coefficient (r) to LLOQ RE: -3.8 to 7.0 % Others RE: to 14.0 % LLOQ RE: 4.0 % ULOQ RE: 3.0 % Precision LLOQ CV: 12.5 % ULOQ CV: 1.9 % LLOQ RE: 5.0 % ULOQ RE: 6.0 % Precision LLOQ CV: 14.3 % ULOQ CV: 3.8 %

15 Intra-batch 0.02, 0.5, 8 ng/ml Inter-batch 0.02, 0.5, 8 ng/ml Stability in Plasma (Short-term Stability) 0.02, 8 ng/ml Room temperature, for 1h, 4h 0.02 ng/ml RE: 2.0 % 0.5 ng/ml RE: 9.4 % 8 ng/ml RE: 6.6 % 0.02 ng/ml CV: 9.3 % Precision 0.5 ng/ml CV: 2.0 % 8 ng/ml CV: 8.6 % 0.02 ng/ml RE: -0.5 % 0.5 ng/ml RE: 0.2 % 8 ng/ml RE: -1.9 % 0.02 ng/ml CV: 14.6 % Precision 0.5 ng/ml CV: 4.0 % 8 ng/ml CV: 3.8 % 0.02 ng/ml RE: 3.5 % 0.5 ng/ml RE: 4.8 % 8 ng/ml RE: 7.4 % 0.02 ng/ml CV: 11.6 % Precision 0.5 ng/ml CV: 6.7 % 8 ng/ml CV: 5.7 % 0.02 ng/ml RE: 4.0 % 0.5 ng/ml RE: 1.8 % 8 ng/ml RE: 5.5 % 0.02 ng/ml CV: 12.5 % Precision 0.5 ng/ml CV: 6.1 % 8 ng/ml CV: 6.6 % 1h 0.02 ng/ml RR: % 8 ng/ml RR: % 4h 0.02 ng/ml RR: % 8 ng/ml RR: % 1h 0.02 ng/ml RR: % 8 ng/ml RR: 90.9 % 4h 0.02 ng/ml RR: 90.9 % 8 ng/ml RR: 89.4 %

16 Stability in Plasma (long-term Stability) 0.02, 8 ng/ml at -20, for 1 week, 2 weeks, 1 month, 2 months, and 6 months Post-preparative stability (Stability in Extract) 0.02, 8 ng/ml in auto-sampler set at 7, for 24h Freeze and Thaw Stability 1 week 0.02 ng/ml RR: % 8 ng/ml RR: 98.0 % 2 weeks 0.02 ng/ml RR: % 8 ng/ml RR: % 1 month 0.02 ng/ml RR: 87.6 % 8 ng/ml RR: 96.9 % 2 months 0.02 ng/ml RR: % 8 ng/ml RR: % 6 months 0.02 ng/ml RR: 93.5 % 8 ng/ml RR: 85.7 % 1 week 0.02 ng/ml RR: 91.9 % 8 ng/ml RR: 97.3 % 2 weeks 0.02 ng/ml RR: % 8 ng/ml RR: % 1 month 0.02 ng/ml RR: % 8 ng/ml RR: % 2 months 0.02 ng/ml RR: % 8 ng/ml RR: 98.3 % 6 months 0.02 ng/ml RR: % 8 ng/ml RR: 85.2 % 0.02 ng/ml RR: % 24h 8 ng/ml RR: % 0.02 ng/ml RR: 99.5 % 24h 8 ng/ml RR: % 3 cycle 0.02 ng/ml RR:108.0 % 8 ng/ml RR: 96.4 % 3 cycle 0.02 ng/ml RR: 96.0 % 8 ng/ml RR: 92.8 %

17 Appropriateness of Dilution Method (using blank plasma) 50 ng/ml 10-fold RE: 2.6 % Precision CV: 2.1 % 100-fold RE: -3.6 % Precision CV: 1.9 % 10-fold RE: 1.4 % Precision CV: 2.8 % 100-fold RE: 4.6 % Precision CV: 4.6 %